Manuel Ruíz Borrego

Author

Manuel Ruíz Borrego

Also Known As

M Ruiz Borrego, M. Borrego, M. Ruiz Borrego, M.R.B. Ruiz Borrego, Manuel Ruiz Borrego, Manuel R. Borrego, Manuel Ruiz Borrego, Manuel Ruíz - Borrego, Manuel Ruíz Borrego, Manuel Ruíz- Borrego

180

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Virgen del Rocío Vall d'Hebron Institute of Oncology Hospital Arnau de Vilanova MedSIR (Spain)Vall d'Hebron Hospital Universitari

About

Manuel Ruíz Borrego is an author at Hospital Universitario Virgen del Rocío specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	20	1.7K
2	Health Sciences	6	6	1K
3	Cell Biology	1	1	21
4	Diabetes	1	1	13
5	Immunology	1	1	13

Manuel Ruíz Borrego

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer David Miles, Joseph Gligorov, Fabrice André, Annals of Oncology	2021	689
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial Fabrice André, Yeon Hee Park, Sung‐Bae Kim, The Lancet Breast OncologyMedicineClinical TrialsBreast CancerPharmacotherapy	2023	313
Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer Miguel Martín, Miguel Ángel Seguí, Antonio Antón, New England Journal of Medicine	2010	208
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4) Miguel Martín, A. Chan, Luc Dirix, Annals of Oncology Breast OncologyMedicinePharmacologyBreast CancerPi3k Inhibitor	2016	178
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial José Manuel Pérez-García, Géraldine Gebhart, Manuel Ruíz Borrego, The Lancet Oncology Breast OncologyMedicineChemotherapy De-escalationPathologyImmune Checkpoint Inhibitor	2021	152
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer Komal Jhaveri, Patrick Neven, M.L. Casalnuovo, New England Journal of Medicine	2024	109
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) &lt; 25: SWOG S1007 (RxPonder) Kevin Kalinsky, William E. Barlow, Funda Meric‐Bernstam, Cancer Research Breast OncologyCancer ManagementGynecologyGynecology OncologyEndocrine Oncology	2021	88
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial Gabriel N. Hortobágyi, Joohyuk Sohn, F. Melo Cruz, Annals of Oncology	2024	70
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study Miguel Martín, Amparo Ruiz Simón, Manuel Ruíz Borrego, Journal of Clinical Oncology	2015	69

Page 1